Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 9, 2000, Pages 2373-2381

  Marchetti, O ^a   Moreillon, P ^a   Glauser, M P ^a   Bille, J ^a   Sanglard, D ^a  

^a Institut de Microbiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMOROLFINE; AMPHOTERICIN B; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; CYCLOSPORIN; CYPROHEPTADINE; DIPYRIDAMOLE; ENZYME INHIBITOR; FLUCONAZOLE; FLUCYTOSINE; FLUPHENAZINE; HALOPERIDOL DECANOATE; LIDOCAINE; LOPERAMIDE; MULTIDRUG EFFLUX TRANSPORTER INHIBITOR; OMEPRAZOLE; PENFLURIDOL; PROTON PUMP INHIBITOR; RESERPINE; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CELL COUNT; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AGAR; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CULTURE MEDIA; CYCLOSPORINE; DRUG SYNERGISM; FLUCONAZOLE; HUMANS; TIME FACTORS;

EID: 0033836026     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.9.2373-2381.2000     Document Type: Article

References (45)

1. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
2. A method of testing for synergy with any number of agents
3. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine
4. Controversies in the management of candidiasis in neutropenic patients treated for malignant diseases: New versus old or better versus worse
5. Azole resistance in Candida
6. International Conference for the development of a consensus on the management and prevention of severe candidal infections
7. Genetic separation of FK 506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter
8. Isogenic strain construction and gene mapping in Candida albicans
9. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A
10. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species
11. Editorial response: Can we agree on the treatment of candidiasis?
12. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture
13. ABC transporters: From microorganisms to man
14. The mechanism of action of cyclosporin A and FK 506
15. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
16. Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo
17. Phase I study of mitoxanthrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
18. + ATPase activity by FK 506 involves calcineurin
19. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
20. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
21. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
22. Cellular functions of immunophilins
23. The trailing endpoint phenotype in antifungal susceptibility testing is pH dependent
24. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids
25. Circumvention of multidrug resistance mediated by P-170 glycoprotein using calcium antagonists in primary human renal cell carcinoma
26. Treatment of murine cryptococcosis with cyclosporin A in normal and athymic mice
27. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
28. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions
29. Calcineurin is required for virulence of Cryptococcus neoformans
30. In vitro and in vivo antifungal activity of cyclosporine
31. Multiple drug resistance in human cancer
32. Method for reliable determination of minimal lethal antibiotic concentrations
33. Tests for bactericidal effects of antimicrobial agents: Technical performance and clinical relevance
34. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
35. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance
36. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
37. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
38. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
39. Characterization of anti-Toxoplasma activity of a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology
40. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukemia
41. Inhibitors of multidrug resistance
42. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs
43. Phase I crossover study of placlitaxel with r-verapamil in patients with metastatic breast cancer
44. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole